Literature DB >> 21371599

Lead generation and examples opinion regarding how to follow up hits.

Masaya Orita1, Kazuki Ohno, Masaichi Warizaya, Yasushi Amano, Tatsuya Niimi.   

Abstract

In fragment-based drug discovery (FBDD), not only identifying the starting fragment hit to be developed but also generating a drug lead from that starting fragment hit is important. Converting fragment hits to leads is generally similar to a high-throughput screening (HTS) hits-to-leads approach in that properties associated with activity for a target protein, such as selectivity against other targets and absorption, distribution, metabolism, excretion, and toxicity (ADME/Tox), and physicochemical properties should be taken into account. However, enhancing the potency of the fragment hit is a key requirement in FBDD, unlike HTS, because initial fragment hits are generally weak. This enhancement is presently achieved by adding additional chemical groups which bind to additional parts of the target protein or by joining or combining two or more hit fragments; however, strategies for effecting greater improvements in effective activity are needed. X-ray analysis is a key technology attractive for converting fragments to drug leads. This method makes it clear whether a fragment hit can act as an anchor and provides insight regarding introduction of functional groups to improve fragment activity. Data on follow-up chemical synthesis of fragment hits has allowed for the differentiation of four different strategies: fragment optimization, fragment linking, fragment self-assembly, and fragment evolution. Here, we discuss our opinion regarding how to follow up on fragment hits, with a focus on the importance of fragment hits as an anchor moiety to so-called hot spots in the target protein using crystallographic data.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21371599     DOI: 10.1016/B978-0-12-381274-2.00015-7

Source DB:  PubMed          Journal:  Methods Enzymol        ISSN: 0076-6879            Impact factor:   1.600


  8 in total

1.  Homology models of mouse and rat estrogen receptor-α ligand-binding domain created by in silico mutagenesis of a human template: molecular docking with 17ß-estradiol, diethylstilbestrol, and paraben analogs.

Authors:  Thomas L Gonzalez; James M Rae; Justin A Colacino; Rudy J Richardson
Journal:  Comput Toxicol       Date:  2018-11-28

2.  Ligand deconstruction: Why some fragment binding positions are conserved and others are not.

Authors:  Dima Kozakov; David R Hall; Stefan Jehle; Sefan Jehle; Lingqi Luo; Stefan O Ochiana; Elizabeth V Jones; Michael Pollastri; Karen N Allen; Adrian Whitty; Sandor Vajda
Journal:  Proc Natl Acad Sci U S A       Date:  2015-04-27       Impact factor: 11.205

3.  Design of a fragment library that maximally represents available chemical space.

Authors:  M N Schulz; J Landström; K Bright; R E Hubbard
Journal:  J Comput Aided Mol Des       Date:  2011-07-27       Impact factor: 3.686

4.  Non-peptidic cruzain inhibitors with trypanocidal activity discovered by virtual screening and in vitro assay.

Authors:  Helton J Wiggers; Josmar R Rocha; William B Fernandes; Renata Sesti-Costa; Zumira A Carneiro; Juliana Cheleski; Albérico B F da Silva; Luiz Juliano; Maria H S Cezari; João S Silva; James H McKerrow; Carlos A Montanari
Journal:  PLoS Negl Trop Dis       Date:  2013-08-22

5.  Auto In Silico Ligand Directing Evolution to Facilitate the Rapid and Efficient Discovery of Drug Lead.

Authors:  Fengxu Wu; Linsheng Zhuo; Fan Wang; Wei Huang; Gefei Hao; Guangfu Yang
Journal:  iScience       Date:  2020-05-18

Review 6.  Concepts and Core Principles of Fragment-Based Drug Design.

Authors:  Philine Kirsch; Alwin M Hartman; Anna K H Hirsch; Martin Empting
Journal:  Molecules       Date:  2019-11-26       Impact factor: 4.411

Review 7.  Applications of Solution NMR in Drug Discovery.

Authors:  Li Shi; Naixia Zhang
Journal:  Molecules       Date:  2021-01-22       Impact factor: 4.411

8.  Fragment-based screening maps inhibitor interactions in the ATP-binding site of checkpoint kinase 2.

Authors:  M Cris Silva-Santisteban; Isaac M Westwood; Kathy Boxall; Nathan Brown; Sam Peacock; Craig McAndrew; Elaine Barrie; Meirion Richards; Amin Mirza; Antony W Oliver; Rosemary Burke; Swen Hoelder; Keith Jones; G Wynne Aherne; Julian Blagg; Ian Collins; Michelle D Garrett; Rob L M van Montfort
Journal:  PLoS One       Date:  2013-06-12       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.